21483-64-7

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl (2-broMothiophen-3-yl)carbaMate is used as a key intermediate in the synthesis of thienopyrazines, which are known to be inhibitors of IRAK4 activity. IRAK4 (interleukin-1 receptor-associated kinase 4) is a crucial enzyme involved in the regulation of inflammatory responses and immune system signaling. Inhibition of IRAK4 can potentially lead to the development of novel therapeutics for the treatment of various inflammatory and autoimmune diseases.
Used in Chemical Synthesis:
In the chemical industry, tert-butyl (2-broMothiophen-3-yl)carbaMate can be utilized as a building block for the creation of more complex molecules with diverse applications. Its unique structural features, including the bromo-thiophene ring and carbamate group, make it a valuable component in the synthesis of various organic compounds, potentially leading to new materials with specific properties and functions.

Upstream product

• 24287-95-4 2-bromothiophene-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 19228-91-2 tert-butyl 3-thienylcarbamate 

Downstream Products

• 335075-94-0 tert-Butyl N-((E)-3-phenylprop-2-enyl)(2-bromo-3-thienyl)carbamate 
• 40826-38-8 Dithieno<3,2-b;2',3'-d>pyridine 

Relevant academic research and scientific papers

Thiophene-Fused 1,4-Diazapentalene: A Stable C=N-Containing π-Conjugated System with Restored Antiaromaticity

A thiophene-fused 1,4-diazapentalene (TAP) was rationally designed and synthesized as a C=N-containing 4n π-electron system that exhibits restored antiaromaticity impaired by the doping with C=N bonds. X-ray crystallographic analysis and quantum chemical

Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

PYRROLOTRIAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrrolotriazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

PYRAZOLOPYRIMIDINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrazolopyrimidine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

THIENOPYRAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to thienopyrazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

PYRROLOPYRIDAZINE INHIBITORS OF IRAK4 ACTIVITY

The present invention relates to pyrrolopyridazine inhibitors of IRAK4 of formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

NOVEL THIENOPYRROLE COMPOUNDS

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treati

Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors

This invention provides estrogen receptor modulators having the structure: wherein R1 to R7 are as defined in the specification; or a pharmaceutically acceptable salt thereof.